Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 12:30 AM ET

Date/Time Source News Release
05/27/2025 08:30 AM EDT GlobeNewswire Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis
05/06/2025 08:30 AM EDT GlobeNewswire Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
05/01/2025 08:30 AM EDT GlobeNewswire Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
04/09/2025 08:30 AM EDT GlobeNewswire Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
03/14/2025 08:30 AM EDT GlobeNewswire Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
03/12/2025 08:30 AM EDT GlobeNewswire Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
03/04/2025 08:30 AM EST GlobeNewswire Palisade Bio Participates in Virtual Investor "What This Means" Segment
02/20/2025 08:45 AM EST GlobeNewswire Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) 
02/19/2025 09:00 AM EST GlobeNewswire Palisade Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
02/10/2025 08:45 AM EST GlobeNewswire Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Page

Additional News

As of June 4, 2025 • 12:30 AM ET

Date/Time Source News Release
05/27/2025 12:01 PM EDT PRISM News Palisade Bio Reports Positive Results from Early-Stage Study of New Treatment for Crohn's and Colitis
05/12/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, May 12th, 2025
05/12/2025 05:31 AM EDT US Earnings Reports Expected earnings - Palisade Bio Inc.
05/06/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: EV & Healthcare Earnings Drive Index Leaders
03/25/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, March 25th, 2025
03/25/2025 05:31 AM EDT US Earnings Reports Expected earnings - Palisade Bio Inc.
03/07/2025 12:00 PM EST Zacks Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - Palisade Bio Inc.
11/12/2024 08:56 AM EST SeekingAlpha Palisade Bio GAAP EPS of -$2.32 beats by $1.03
10/31/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Thu, Oct 31, 2024 as of 10.00 am ET
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.